PUBLIC COMPANY
saveLEO Pharma Inc
updated 4mo ago
community read0 votes
🐶 often sniffed alongside
top 7pipeline
3
marketed
3
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
3Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 7d ago
- Leo Pharma buys rare skin disease drug in $435M dealTanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight.biopharma_dive · 1mo ago
- LEO adds to dermatology portfolio with $435M deal for late-stage rare disease drugThis is the third recent acquisition conducted by Denmark’s LEO Pharma in medical dermatology, a portfolio that marked 12% growth in the first half of the year.biospace · 1mo ago
- Leo Pharma to license Tanabe’s rare disease drug for pain with sun exposureLeo Pharma said it will pay Japan’s Tanabe Pharma up to $435 million in upfront and near-term payments to license an oral drug for a pair of genetic light-sensitive skin diseases. The Danish biotec…endpoints · 1mo ago
- Leo ‘really strengthening’ pipeline with $435M deal for Tanabe rare skin disease drug awaiting FDA nodLeo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the…fiercebiotech · 1mo ago
- Chasing Dupixent, a biotech aims to make better antibody drugs for eczemaInfinimmune, a California startup, is developing treatments it claims might last longer and be more effective than existing atopic dermatitis medications.biopharma_dive · 1mo ago
comments(0)
5-min edit window · permanent after that